Macquarie Group’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-14,718
| Closed | -$316K | – | 2205 |
|
|
2024
Q1 | $316K | Hold |
14,718
| – | – | ﹤0.01% | 1484 |
|
|
2023
Q4 | $54K | Hold |
14,718
| – | – | ﹤0.01% | 1593 |
|
|
2023
Q3 | $57K | Buy |
+14,718
| New | +$57.5K | ﹤0.01% | 1583 |
|
|
2023
Q2 | – | Sell |
-14,718
| Closed | -$44K | – | 1754 |
|
|
2023
Q1 | $44K | Hold |
14,718
| – | – | ﹤0.01% | 1644 |
|
|
2022
Q4 | $74K | Hold |
14,718
| – | – | ﹤0.01% | 1655 |
|
|
2022
Q3 | $96K | Hold |
14,718
| – | – | ﹤0.01% | 1778 |
|
|
2022
Q2 | $107K | Hold |
14,718
| – | – | ﹤0.01% | 1857 |
|
|
2022
Q1 | $217 | Hold |
14,718
| – | – | ﹤0.01% | 1795 |
|
|
2021
Q4 | $706K | Hold |
14,718
| – | – | ﹤0.01% | 1616 |
|
|
2021
Q3 | $2.15M | Hold |
14,718
| – | – | ﹤0.01% | 1368 |
|
|
2021
Q2 | $1.7M | Hold |
14,718
| – | – | ﹤0.01% | 1461 |
|
|
2021
Q1 | $1.42M | Buy |
+14,718
| New | +$1.92M | ﹤0.01% | 1306 |
|
Macquarie Group's LABP Position: Q2 2024 in Review
Macquarie Group sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2024, closing a stake of 14,718 shares — an estimated $316K sold.
Macquarie Group first reported a position in LABP in Q1 2021 and held it in 12 quarters. The position peaked at $2.15M in Q3 2021. 0 funds tracked by Wall St. Rank hold LABP as of Q2 2024.
- Macquarie Group reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Macquarie Group sold 14,718 Landos Biopharma, Inc. Common Stock shares in Q2 2024, an estimated $316K.
- Macquarie Group first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 12 quarters.
- Macquarie Group's Landos Biopharma, Inc. Common Stock position peaked at $2.15M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2024.
Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.